Table 5.
Comparison of Fatigue and QoL outcomes in mCRPC patients
| HT (n = 75) |
AAP < 3 months (n = 33) | AAP ≥ 3 months (n = 43) | p-value | p-value AAP ≥ 3 months vs AAP < 3 months |
p-value
AAP ≥ 3 months vs HT |
|
|---|---|---|---|---|---|---|
| Fatigue intensity (BFI item 3) | 3.0 (0.0–10.0) | 4.0 (0.0–8.0) | 2.0 (0.0–9.0) | 0.125a | 0.243 | 0.043 |
| Fatigue severity, n (%) | 0.039 | – | – | |||
| No fatigue | 15 (20.0) | 10 (30.3) | 13 (30.2) | |||
| Mild fatigue | 29 (38.7) | 8 (24.2) | 19 (44.2) | |||
| Moderate fatigue | 18 (24.0) | 14 (42.4) | 9 (20.9) | |||
| Severe fatigue | 13 (17.3) | 1 (3.0) | 2 (4.7) | |||
| Interference (BFI item 4A-4F) | 2.7 (0.0–9.0) | 2.7 (0.0–7.0) | 1.8 (0.0–10.0) | 0.106b | 0.473 | 0.04 |
| FACT-G overall score | 77.0 (24.7–101.0) | 81.0 (35.0–101.0) | 83.0 (38.0–103.0) | 0.121c | 0.429 | 0.046 |
| FACT-P overall score | 108.3 (50.7–140.0) | 114.3 (57.0–137.0) | 117.0 (61.0–138.0) | 0.052d | 0.402 | 0.018 |
| Physical WB | 22.0 (4.0–28.0) | 24.0 (12.0–28.0) | 24.0 (9.0–28.0) | 0.031e | 0.643 | 0.014 |
| Social / Family WB | 21.0 (3.0–28.0) | 21.0 (2.0–28.0) | 20.0 (11.0–28.0) | 0.834 | – | – |
| Emotional WB | 17.0 (3.0–24.0) | 17.0 (7.0–23.0) | 18.0 (7.0–23.0) | 0.727 | – | – |
| Functional WB | 17.0 (0.0–28.0) | 19.0 (3.0–27.0) | 21.0 (6.0–28.0) | 0.041f | 0.054 | 0.017 |
| Prostate cancer subscale | 30.0 (11.0–42.0) | 32.0 (17.0–43.0) | 34.0 (20.0–43.0) | 0.029g | 0.462 | 0.008 |
Data are expressed as median (IQR), unless otherwise stated
AAP Abiraterone Acetate-prednisone, HT traditional hormone therapy, IQR interquartile range, WB well-being